← 홈

ADC

233개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 233개
ADCSHOTFDACuratedFDABiologicDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 79.7%임상시험 215상태 APPROVED
ADCSHOTFDACuratedFDABiologicRocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 80%임상시험 159상태 APPROVED
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCSHotBiologicImmunityBio, Inc.Phase 3

Nab-paclitaxel (Nab-paclitaxel)

Triple Negative Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 69.1%임상시험 216상태 RECRUITING
ADCAHotBiologicCellerant TherapeuticsVedotin Therapy]Phase 3

Filgrastim (Filgrastim)

Male Breast Cancer; Stage II Breast Cancer · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88%임상시험 142상태 RECRUITING
ADCAHotBiologicChia Tai Tianqing Pharmaceutica…Phase 3

Capecitabine/Paclitaxel/Albumin Paclitaxel (Chemotherapy drug, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+2
효능 ORR 60.4%임상시험 133상태 RECRUITING
ADCBHotBiologicNCIC Clinical Trials Groupvedotin, 120 mg intr…Phase 3

Epirubicin (Epirubicin)

Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 62.7%임상시험 108상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 106상태 RECRUITING
ADCBBiologicGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 87상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCSBiologicRochederuxtecan (Dato-DXd, Datro…Phase 3

T-DXd (Trastuzumab-Deruxtecan, Trastuzumab-Deruxtecan (T-DXd))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 79.7%임상시험 83상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Approved#인기#항체약물접합체+4
효능 ORR 65.8%임상시험 78상태 RECRUITING
ADCCBiologicRemeGenvedotin plus PD-1 blockade …Phase 3

RC48 (Disitamab Vedotin, Disitamab Vedotin (RC48))

HER2 + Breast Cancer · mCRPC

#mCRPC#ADC#Phase3#인기#항체약물접합체+5
임상시험 76상태 RECRUITING
ADCABiologicRocheDM1) and trastuzumab deruxt…Phase 3

ado-trastuzumab emtansine (Kadcyla, T-DM1)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 80%임상시험 76상태 RECRUITING
ADCBBiologicMerck Sharp & Dohme LLCPhase 2

Cytoxan (Cytoxan)

Multiple Myeloma, Refractory · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 73상태 RECRUITING
ADCSBiologicShanghai Juncell TherapeuticsApproved

Hydroxychloroquine (Hydroxychloroquine)

Psoriasis; Atopic Dermatitis · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Approved#인기#항체약물접합체+4
효능 ORR 75%임상시험 70상태 ACTIVE
ADCBiologicUNICANCERPhase 2

Epirubicin hydrochloride (Epirubicin hydrochloride)

Breast Cancer · Breast Neoplasms

#BreastNeoplasms#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 43.3%임상시험 68상태 RECRUITING
ADCBiologicSpanish Breast Cancer Research …sPhase 2

Taxotere (Taxotere)

Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 88.1%임상시험 68상태 RECRUITING

1 / 12 페이지

← 이전다음 →